Serum S100B levels in patients with obstructive sleep apnea syndrome

Objectives: Obstructive sleep apnea syndrome (OSAS)which is characterized by recurrent pharyngeal narrowingand breathing disturbances, can affect central neuralsystem (CNS). S100B, which exerts neurotrophic andgliotrophic features, is a calcium binding protein. The aimof this study was to evaluate serum levels of S100B inpatients with OSAS.Materials and methods: Clinical and laboratory assessmentwere performed in 26 patients (5 women and 21men) with OSAS and 28 (8 women and 20 men) age-,body mass index (BMI)- and sex- matched healthy subjectsserved as controls . The patients included in thestudy had whole-night polysomnography (PSG) performedin the sleep laboratory. Measurements of S100Bwere done using the commercially available ELISA kit.Results: Patients and controls were well matched withregard to demographic characteristics. Serum S100Bconcentrations were 149.4±84.5 ng/L and 139.2±70.7ng/L for patients with OSAS and control subject, respectively.There was no statistically significant difference inserum S100B concentrations between OSAS and controlgroups (p>0.05).Conclusions: Serum S100B protein level in serum didnot significantly higher in patients with OSAS comparedto the healthy subjects. However, further investigationsare required, particularly in the area of biochemical markersof mild cerebral damage in patients with OSAS. J ClinExp Invest 2012; 3 (3): 345-349Key words: Obstructive sleep apnea syndrome, serumS100B, brain, polysomnography